Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Dassault Systèmes SE
  6. News
  7. Summary
    DSY   FR0014003TT8

DASSAULT SYSTÈMES SE

(DSY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dassault Systemes : Labcorp Selects Medidata's Sensor Cloud to Expand Decentralized Clinical Trial Capabilities, Enabling First-in-Kind Industry Partnership for Digital Biomarker Discovery

09/14/2021 | 05:10am EDT

* The Agreement Introduces a New Collaboration Model to Advance the Use of Medical-Grade Sensors and Accelerate Biomarker Discovery

New York -- Medidata, a Dassault Systemes company, and Labcorp Drug Development, a global company providing clinical laboratory and end-to-end drug development services, today announced they have entered into an agreement using the Medidata Sensor Cloud. Medidata will receive and process medical-grade sensor data within drug, vaccine and device trials across Labcorp Drug Development's clinical trial portfolio, enhancing their decentralized clinical trial (DCT) offerings.

Sensor Cloud is a transformative platform for managing a broad range of sensor and digital health technology data and establishing interoperability with other clinical data sources. Launched earlier this year, Sensor Cloud integrates seamlessly with the Medidata Clinical Cloud and supports remote, continuous patient data collection from both Medidata and third-party, medical-grade sensors. This innovation provides a more comprehensive view of the patient experience through cutting-edge data ingestion, data standardization across all sensor types, and deep analytical capabilities that will ultimately lead to new digital biomarker discovery and digital endpoint deployment.

"Sensor Cloud solves key technical, operational, and analytical challenges that have historically stifled the widespread usage of medical devices in clinical research," said Ben Schlatka, vice president of digital biomarker solutions at Medidata. "This technology is urgently needed, with device usage dramatically escalating as patients, sponsors and sites demand greater flexibility during clinical trials. Combining the power of Sensor Cloud with Labcorp's innovative approach to clinical research and its scale in clinical diagnostics will transform how patient data are collected, managed, analyzed and leveraged-driving faster, more effective drug development and overall better health outcomes."

In addition, Labcorp and Medidata will use Sensor Cloud to co-develop digital biomarkers across a broad array of medical devices and therapeutic areas. The goal of this first-of-its-kind collaboration is to build a library of digital biomarkers that can be used to advance therapeutic research and create new, digital diagnostics. The first project will be an at-home version of the Six Minute Walk Test (6MWT), which is widely used in clinics to measure functional capacity in patients with heart failure, pulmonary conditions, physical function disorders and rare diseases.

"High-quality, medical-grade sensors offer the potential to understand patient disease processes with objective digital precision in a real-world setting, replacing subjective assessments that have limited clinical value," said Bill Hanlon, PhD, president of Clinical Therapeutic and Regulatory Sciences at Labcorp Drug Development. "Labcorp's collaboration with Medidata is poised to advance sensor and digital biomarker usage in clinical research in an unprecedented fashion, and will make clinical research and care processes more patient-centric, risk-based, efficient, personalized, and informative."

Digital biomarkers are often defined as objective, quantifiable physiological and behavioral data collected and measured by digital devices such as portable, wearable, implantable, or digestible sensors. The data collected are typically used to explain, influence and/or predict health-related outcomes. But, before the data can be truly useful to researchers, patients and clinicians, it must be captured, standardized and interoperable. In this way, Sensor Cloud's capabilities make it a foundational tool for sensor usage in clinical research and development.

Medidata is a wholly owned subsidiary of Dassault Systemes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
DASSAULT SYSTÈMES SE 0.01% 46.63 Real-time Quote.40.43%
LABORATORY CORPORATION OF AMERICA HOLDINGS 0.84% 282.15 Delayed Quote.38.61%
All news about DASSAULT SYSTÈMES SE
10/14DASSAULT SYSTEMES : Systèmes to Publish its Third Quarter 2021 Results, Webcast and Confer..
AQ
10/14Bloom SAS announced that it has received €11 million in funding from Dassault Systèmes ..
CI
10/12SYNOPSYS : and Dassault Systemes Partner to Enable Industry's First Holistic Lighting Desi..
AQ
10/12DASSAULT SYSTEMES : Synopsys and Dassault Systèmes Partner to Enable Industry's First Holi..
PU
10/12DASSAULT SYSTEMES : Synopsys and Dassault Systèmes Partner to Enable Industry's First Holi..
PR
10/11GLOBAL MARKETS LIVE : Facebook, Apple, KKR, Adler, Roche...
10/11DASSAULT SYSTEMES : Systèmes announces the launch of a global employee shareholding progra..
AQ
10/07DASSAULT SYSTEMES : Launches 3DEXPERIENCE Edu Centers of Excellence, Its Global Program to..
AQ
10/07Dassault Systèmes Launches 3DEXPERIENCE Edu Centers of Excellence, Its Global Program t..
CI
10/06DASSAULT SYSTEMES : Rho Selects Medidata's Industry-Leading Decentralized Clinical Trial C..
AQ
More news
Financials
Sales 2021 4 809 M 5 603 M 5 603 M
Net income 2021 758 M 884 M 884 M
Net Debt 2021 969 M 1 129 M 1 129 M
P/E ratio 2021 80,9x
Yield 2021 0,35%
Capitalization 61 352 M 71 364 M 71 486 M
EV / Sales 2021 13,0x
EV / Sales 2022 11,6x
Nbr of Employees 20 000
Free-Float 50,0%
Chart DASSAULT SYSTÈMES SE
Duration : Period :
Dassault Systèmes SE Technical Analysis Chart | DSY | FR0014003TT8 | MarketScreener
Technical analysis trends DASSAULT SYSTÈMES SE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Last Close Price 46,67 €
Average target price 46,38 €
Spread / Average Target -0,61%
EPS Revisions
Managers and Directors
Bernard Charlès Vice Chairman & Chief Executive Officer
Dominique Florack President
Pascal Daloz Chief Operating & Financial Officer
Charles Edelstenne Chairman
Laurence Barthès Executive VP, Chief People & Information Officer
Sector and Competitors
1st jan.Capi. (M$)
DASSAULT SYSTÈMES SE40.43%71 364
MICROSOFT CORPORATION39.00%2 321 142
SEA LIMITED78.50%196 181
ATLASSIAN CORPORATION PLC80.96%106 965
ZOOM VIDEO COMMUNICATIONS, INC.-17.71%82 477
SYNOPSYS INC.23.87%48 972